VIR BIOTECHNOLOGY, I

VIR
Delayed Quote. Delayed  - 05/13 04:00:00 pm
39.55USD +1.13%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Other Biotechnology & Medical Research
Vir Biotechnology, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments to treat and prevent serious infectious diseases. Its technology platforms are focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA). Its pipeline consists of product candidates targeting hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its product candidates include VIR-2218, VIR-3434, VIR-2482, VIR-1111 and VIR-2020. The Company is developing VIR-2218 and VIR-3434 for the functional cure of HBV. VIR-2218 is a subcutaneously administered HBV-targeting siRNA. VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody (mAb). VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb. VIR-1111 is a subcutaneously administered HIV T cell vaccine. VIR-2020 is a subcutaneously administered TB T cell vaccine.

Number of employees : 327 people.
Sales per Business
2020
USD
(in Million)
%
Contract 44.5058.3%
License 22.7529.8%
Grant 9.1211.9%
Sales per region
20192020
USD
(in Million)
%USD
(in Million)
%
United States 8.09100% 76.37100%
Managers
Name Title
George A. Scangos President, Chief Executive Officer & Director
Howard Horn CFO, Secretary & Principal Accounting Officer
Vicki L. Sato Non-Executive Chairman
Michael E. Kamarck Chief Technology Officer
Phil Pang Chief Medical Officer
Herbert W. Virgin Chief Scientific Officer & Executive VP-Research
Steven Rice Chief Administrative Officer
Robert Taylor Nelsen Independent Director
Robert J. Perez Independent Director
Phillip A. Sharp Independent Director
Shareholders
Name Equities %
ARCH Venture Partners LLC 26,690,617 20.9%
SB Investment Advisers (UK) Ltd. 22,616,666 17.7%
Capital Research & Management Co. (International Investors) 11,300,804 8.84%
GlaxoSmithKline plc 6,626,027 5.18%
George Scangos 6,520,888 5.10%
Capital Research & Management Co. (World Investors) 5,867,608 4.59%
The Vanguard Group, Inc. 5,720,146 4.47%
Capital Research & Management Co. (Global Investors) 5,684,370 4.45%
Temasek Holdings Pte Ltd. (Investment Management) 5,499,999 4.30%
Alaska Permanent Fund Corp. 3,893,040 3.05%
Company contact information
Vir Biotechnology, Inc.
499 Illinois Street
Suite 500
5th floor
San Francisco, CA 94158

Phone : +1.415.906.4324
Web : http://www.vir.bio
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
VIR BIOTECHNOLOGY, INC.47.68%5 086
MODERNA, INC.46.15%61 305
LONZA GROUP AG-1.83%45 649
IQVIA HOLDINGS INC.27.25%43 699
CELLTRION, INC.-26.18%31 675
SEAGEN INC.-17.34%26 272
CUREVAC N.V.15.90%21 497
HANGZHOU TIGERMED CONSULTING CO.,LTD-5.82%20 632
PHARMARON BEIJING CO., LTD.36.88%20 564
INCYTE CORPORATION-7.29%18 115
PPD, INC.34.66%16 173
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.28.27%15 918
BIO-TECHNE CORPORATION28.76%15 902
ALNYLAM PHARMACEUTICALS, INC.2.61%15 676
ICON PUBLIC LIMITED COMPANY15.02%11 855
PRA HEALTH SCIENCES, INC.35.62%11 023
QIAGEN N.V.-12.43%10 571
NOVAVAX, INC.14.63%9 467
SYNEOS HEALTH, INC.24.72%8 822
UNITED THERAPEUTICS CORPORATION28.79%8 757
ABCELLERA BIOLOGICS INC.-23.66%8 323